Litcius/Paper detail

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa McKiver, Mark Cook, Paula Rodríguez‐Otero

2024The Lancet Haematology25 citationsDOI

Topics & Concepts

MedicineQuality of life (healthcare)Multiple myelomaRefractory (planetary science)Internal medicinePediatricsOncologyNursingAstrobiologyPhysicsMultiple Myeloma Research and TreatmentsCAR-T cell therapy researchCancer Immunotherapy and Biomarkers
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial | Litcius